Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
Amarin Announces 30th Patent for Vascepa(R) Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces 30th Patent for Vascepa(R)
Amarin to Present at the 2013 Aegis Capital Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the 2013 Aegis Capital Healthcare Conference
Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients
Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled
Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa(R) Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa(R)
Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR Indication
Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia
Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote
Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
